Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides

NCT01187446 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

28

Enrollment

OTHER

Sponsor class

Stopped Business decision by funding source

Conditions

Cutaneous Lymphoma
Cutaneous T-cell Lymphoma

Interventions

RADIATION: Total skin electron beam therapy (TSEBT)
DRUG: Vorinostat

Sponsor

Stanford University